Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, San Francisco, Scarborough, and Washington D.C., United StatesSee the 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 104 people enrolled
- Started
- 17 Dec 2021
- Ended
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Single Arm
- Neonatal Neurobehavioral Scale
- Record updated
- 14 July 2026
Who can take part
- Age
- 0 years to 52 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Pregnant women 18 years of age and over with a singleton fetus with known or suspected congenital heart disease anticipated to need intervention or surgery within 30 days of birth
Who cannot take part
- Fetal extra-cardiac anomalies
- Known fetal chromosomal or genetic abnormalities
- Multiple gestation pregnancy
Where in United States
- Primary Children's HospitalSalt Lake City, United States
- University of UtahSalt Lake City, United States
- University of California San FranciscoSan Francisco, United States
- Maine Medical CenterScarborough, United States
- Children's National Medical CenterWashington D.C., United States
About the trial
What the trial wants to find out
Determine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as chronic congenital heart disease (CCHD) lesion, maternal-fetal environment, and social determinants of heath (SDOH) in a diverse population using a multicenter design.
Read full original descriptionShow less
Pregnant women will be approached during one of their fetal cardiology clinic visits.
The group in the trial
- Single ArmTreatment being tested
Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.
Treatment: Single Arm and Neonatal Neurobehavioral Scale
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 14 July 2026